查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球生物模擬市場：增長、未來展望、競爭分析 (2022-2030)
市場調查報告書
商品編碼
1166626

全球生物模擬市場：增長、未來展望、競爭分析 (2022-2030)

Biosimulation Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日期: | 出版商: Acute Market Reports | 英文 120 Pages | 商品交期: 最快1-2個工作天內

價格

從應用領域來看，全球生物模擬市場中，藥物研發領域佔比較大。 這部分是由於越來越需要減少與目前用於治療的藥物相關的副作用。 此外，藥物開發中基於計算機的建模成功率的顯著提高導致需求增加。 由於人們越來越認識到生物模擬的好處，例如縮小阻礙藥物發現過程的差距，這反過來又降低了藥物發現的失敗率，預計藥物發現領域在預測期內也將增長。

按地區劃分，北美所佔份額最大。 關鍵因素包括藥物開發啟動的增加、嚴格的監管政策、臨床試驗前對預分析的需求增加，以及製藥公司/研究機構與芯片開發人員之間的戰略合作夥伴關係增加。您可以 預計在 2022-2030 年的預測期內，亞太地區的生物模擬市場將呈現正增長。

在這份報告中，我們分析了全球生物模擬市場，包括市場的基本結構、宏觀和微觀環境因素、整體市場規模趨勢展望（2020-2030），以及按類型和應用劃分。□我們將彙編和發布信息，例如各地區的詳細趨勢、主要市場驅動因素和製約因素、主要公司的概況和增長戰略。

內容

第一章介紹

第 2 章執行摘要

第 3 章生物模擬市場：競爭分析

  • 生物模擬市場：主要供應商的市場定位
  • 供應商在生物模擬市場採用的策略
  • 主要行業戰略
  • 層次分析 (2021/2030)

第 4 章生物模擬市場：宏觀分析和市場動態

  • 介紹
  • 全球生物模擬市場規模（單位：百萬美元，2020-2030 年）
  • 市場動態
    • 市場驅動因素
    • 市場製約因素
    • 主要問題
    • 主要機會
  • 促進因素和抑制因素的影響分析
  • 蹺蹺板分析

第 5 章生物模擬市場：按類型（單位：百萬美元，2020-2030）

  • 市場概覽
  • 增長和收益分析 (2021/2030)
  • 市場細分
    • PK/PD 建模和仿真軟件
    • 分子建模和模擬軟件
    • PBPK 建模和仿真軟件
    • 毒性預測軟件
    • 臨床試驗設計軟件
    • 其他軟件

第 6 章生物模擬市場：按應用（單位：百萬美元，2020-2030）

  • 市場概覽
  • 增長和收益分析 (2021/2030)
  • 市場細分
    • 藥物開發
    • 藥物發現

第7章北美生物模擬市場（單位：百萬美元，2020-2030）

  • 市場概覽
  • 生物模擬市場：按類型分類（單位：百萬美元，2020-2030 年）
  • 生物模擬市場：按應用分類（單位：百萬美元，2020-2030 年）
  • 生物模擬市場：按地區（單位：百萬美元，2020-2030 年）
    • 北美

第8章英國和歐盟國家的生物模擬市場（單位：百萬美元，2020-2030）

第9章亞太生物模擬市場（單位：百萬美元，2020-2030）

第十章拉丁美洲生物模擬市場（單位：百萬美元，2020-2030）

第 11 章中東和非洲的生物模擬市場（單位：百萬美元，2020-2030 年）

第12章公司簡介

  • Medtronic
  • Certara USA, Inc.
  • Simulation Plus, Inc.
  • Dassault Systems SA
  • Schrodinger, Inc.
  • Advanced Chemistry Development, Inc.
  • Chemical Computing Group, Inc.
  • Physiomics PLC
  • Entelos, Inc.
  • Rhenovia Pharma Ltd.
  • Genedata AG
  • Evidera, Inc.
  • In Silico Biosciences Inc.
  • Oxford Drug Design
  • Insilico Biotechnology AG
  • Leadinvent technologies Pvt Ltd.
  • Leadscope, Inc.
Product Code: 137792-08-22

The report titled "Global Biosimulation Market: Growth, Future Prospects, and Competitive Analysis, 2022 -2030" offers strategic insights into the overall biosimulation market along with the market size and estimates for the duration of 2020 to 2030. The said research study covers in-depth analysis of biosimulation market segments based on software type, application and different geographies further segmented by countries. Biosimulation techniques are the newest additions to the drug development industry which is based on simulation of biologic process via computer programs. This technique is widely used to predict the path of drug development and has proven beneficial in reducing patient numbers, time and cost incurred in the entire drug development process, thus proving beneficial for the pharmaceutical industries for its overall growth. Owing to the aforementioned benefits and an increase in awareness, demand and adoption of biosimulation, this market is presumed to have an increased growth in the forecasted period of 2022-2030.

Market size estimates and forecast for these segments for the period 2020 to 2030 are provided in terms of US$ Mn along with the respective compounded annual growth rates (CAGRs) for the period 2022 to 2030, considering 2021 as the base year.

The geographical segmentation of the global biosimulation market comprised regions such as North America, Europe, Asia-Pacific, Latin America & Middle East and Africa. Each geographical region is further split to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, Brazil, Mexico, Saudi Arabia, South Africa, and other countries. Market size and forecast for these segments during 2020 to 2030 and their CAGRs for the period 2022 to 2030 are provided in this report.

The biosimulation market is observed as the most diversified and competitive market comprising large number of players. The market is dominated by several players, depending on their major competencies. The key players in this market are Certara USA, Inc., Simulation Plus, Inc., Dassault Systems SA, Schrodinger, Inc., Advanced Chemistry Development, Inc., Chemical Computing Group, Inc., Physiomics PLC, Entelos, Inc., Rhenovia Pharma Ltd., Genedata AG, Evidera, Inc., In Silico Biosciences Inc., Oxford Drug Design, Insilico Biotechnology AG, Leadinvent technologies Pvt Ltd. & Leadscope, Inc.

Within this segment showcases a highly consolidated market share, as each and every software would be used during the course of drug development. Each modeling and simulation software are essential in predicting each step of drug development. These software's would determine the course of a clinical trial and assess its success rate. Comparatively the PK/PD modeling and simulation software, molecular modeling and simulation software have a marginally higher market share owing to its majorly used applications such as dosage designing before a clinical trial, pharmacokinetic profiling of a drug or the success rate of drug administration on treatment outcome.

The drug development segment encapsulates a larger share in the biosimulation market. This dominance is attributed due to increase in need for reduction in adverse effects associated with the current drugs available for treatment, which is propelling the demand for in silico systems to aid in development of improved molecules. The increased demand is also due to significant increase in success rates of computer based modeling in drug development. The drug discovery segment is also expected to grow in the forecast period of 2022-2030 owing to growing awareness of benefits of biosimulation such as bridging the gaps that hinder the drug discovery process which would enable lowering the drug failure rates. The demand for biosimulation in drug discovery would also rise in the forecast period as there would be an increased demand for personalized medicines which would require lead/target identification and optimization.

Biosimulation provides simulation of biological system thus rendering most beneficial in the clinical trial development thus preventing the risks of drug failures. For the purpose of this study, the global biosimulation market is segmented into regional markets viz., North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Of the aforementioned regions, North America encapsulated the largest share in the biosimulation market. The major factors that drive this predominance in the North American market are increase in drug development initiations, stringent regulatory policies ensuring patient safety and efficacy standards thus raising the demand to pre-analyze the success rate of the molecule before entering clinical trials, rise in number of strategic collaborations between pharmaceutical industries/research institute and in silico developers for simulation based drug development. Asia-Pacific is projected to show a positive growth biosimulation market during the forecast period, 2022-2030. The drivers propelling this market are increasing presence of CRO's, development of healthcare infrastructure, penetration of healthcare IT and an extensive initiation of research and development activities.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Biosimulation market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Biosimulation market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Type

  • PK/PD Modeling and Simulation Software
  • Molecular Modeling and Simulation Software
  • PBPK Modeling and Simulation Software
  • Toxicity Prediction Software
  • Trial Design Software
  • Other Software's.

Application

  • Drug Development
  • Preclinical testing
  • Clinical trials
  • Drug Discovery

Region Segment (2020-2030; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

  • Pre COVID-19 situation
  • Post COVID-19 situation

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Biosimulation market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Biosimulation market?
  • Which is the largest regional market for Biosimulation market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Biosimulation market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Biosimulation market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Biosimulation Market
  • 2.2. Global Biosimulation Market, By Type, 2021 (US$ Million)
  • 2.3. Global Biosimulation Market, By Application, 2021 (US$ Million)
  • 2.4. Global Biosimulation Market, By Geography, 2021 (US$ Million)
  • 2.5. Attractive Investment Proposition by Geography, 2021

3. Biosimulation Market: Competitive Analysis

  • 3.1. Market Positioning of Key Biosimulation Market Vendors
  • 3.2. Strategies Adopted by Biosimulation Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2021 Versus 2030

4. Biosimulation Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Biosimulation Market Value, 2020 - 2030, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Biosimulation Market: By Type, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. PK/PD Modeling and Simulation Software
    • 5.3.2. Molecular Modeling and Simulation Software
    • 5.3.3. PBPK Modeling and Simulation Software
    • 5.3.4. Toxicity Prediction Software
    • 5.3.5. Trial Design Software
    • 5.3.6. Other Software's.

6. Biosimulation Market: By Application, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 6.3. Market Segmentation
    • 6.3.1. Drug Development
      • 6.3.1.1. Preclinical testing
      • 6.3.1.2. Clinical trials
    • 6.3.2. Drug Discovery

7. North America Biosimulation Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Biosimulation Market: By Type, 2020-2030, USD (Million)
  • 7.3. Biosimulation Market: By Application, 2020-2030, USD (Million)
  • 7.4.Biosimulation Market: By Region, 2020-2030, USD (Million)
    • 7.4.1.North America
      • 7.4.1.1. U.S.
        • 7.4.1.1.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 7.4.1.1.1. Biosimulation Market: By Application, 2020-2030, USD (Million)
      • 7.4.1.2. Canada
        • 7.4.1.2.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 7.4.1.2.1. Biosimulation Market: By Application, 2020-2030, USD (Million)
      • 7.4.1.3. Rest of North America
        • 7.4.1.3.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 7.4.1.3.1. Biosimulation Market: By Application, 2020-2030, USD (Million)

8. UK and European Union Biosimulation Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Biosimulation Market: By Type, 2020-2030, USD (Million)
  • 8.3. Biosimulation Market: By Application, 2020-2030, USD (Million)
  • 8.4.Biosimulation Market: By Region, 2020-2030, USD (Million)
    • 8.4.1.UK and European Union
      • 8.4.1.1. UK
        • 8.4.1.1.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 8.4.1.1.1. Biosimulation Market: By Application, 2020-2030, USD (Million)
      • 8.4.1.2. Germany
        • 8.4.1.2.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 8.4.1.2.1. Biosimulation Market: By Application, 2020-2030, USD (Million)
      • 8.4.1.3. Spain
        • 8.4.1.3.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 8.4.1.3.1. Biosimulation Market: By Application, 2020-2030, USD (Million)
      • 8.4.1.4. Italy
        • 8.4.1.4.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 8.4.1.4.1. Biosimulation Market: By Application, 2020-2030, USD (Million)
      • 8.4.1.5. France
        • 8.4.1.5.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 8.4.1.5.1. Biosimulation Market: By Application, 2020-2030, USD (Million)
      • 8.4.1.6. Rest of Europe
        • 8.4.1.6.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 8.4.1.6.1. Biosimulation Market: By Application, 2020-2030, USD (Million)

9. Asia Pacific Biosimulation Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Biosimulation Market: By Type, 2020-2030, USD (Million)
  • 9.3. Biosimulation Market: By Application, 2020-2030, USD (Million)
  • 9.4.Biosimulation Market: By Region, 2020-2030, USD (Million)
    • 9.4.1.Asia Pacific
      • 9.4.1.1. China
        • 9.4.1.1.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 9.4.1.1.1. Biosimulation Market: By Application, 2020-2030, USD (Million)
      • 9.4.1.2. Japan
        • 9.4.1.2.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 9.4.1.2.1. Biosimulation Market: By Application, 2020-2030, USD (Million)
      • 9.4.1.3. India
        • 9.4.1.3.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 9.4.1.3.1. Biosimulation Market: By Application, 2020-2030, USD (Million)
      • 9.4.1.4. Australia
        • 9.4.1.4.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 9.4.1.4.1. Biosimulation Market: By Application, 2020-2030, USD (Million)
      • 9.4.1.5. South Korea
        • 9.4.1.5.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 9.4.1.5.1. Biosimulation Market: By Application, 2020-2030, USD (Million)
      • 9.4.1.6. Rest of Asia Pacific
        • 9.4.1.6.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 9.4.1.6.1. Biosimulation Market: By Application, 2020-2030, USD (Million)

10. Latin America Biosimulation Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Biosimulation Market: By Type, 2020-2030, USD (Million)
  • 10.3. Biosimulation Market: By Application, 2020-2030, USD (Million)
  • 10.4.Biosimulation Market: By Region, 2020-2030, USD (Million)
    • 10.4.1.Latin America
      • 10.4.1.1. Brazil
        • 10.4.1.1.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 10.4.1.1.1. Biosimulation Market: By Application, 2020-2030, USD (Million)
      • 10.4.1.2. Mexico
        • 10.4.1.2.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 10.4.1.2.1. Biosimulation Market: By Application, 2020-2030, USD (Million)
      • 10.4.1.3. Rest of Latin America
        • 10.4.1.3.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 10.4.1.3.1. Biosimulation Market: By Application, 2020-2030, USD (Million)

11. Middle East and Africa Biosimulation Market, 2020-2030, USD (Million)

  • 11.1. Market Overview
  • 11.2. Biosimulation Market: By Type, 2020-2030, USD (Million)
  • 11.3. Biosimulation Market: By Application, 2020-2030, USD (Million)
  • 11.4.Biosimulation Market: By Region, 2020-2030, USD (Million)
    • 11.4.1.Middle East and Africa
      • 11.4.1.1. GCC
        • 11.4.1.1.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 11.4.1.1.1. Biosimulation Market: By Application, 2020-2030, USD (Million)
      • 11.4.1.2. Africa
        • 11.4.1.2.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 11.4.1.2.1. Biosimulation Market: By Application, 2020-2030, USD (Million)
      • 11.4.1.3. Rest of Middle East and Africa
        • 11.4.1.3.1. Biosimulation Market: By Type, 2020-2030, USD (Million)
        • 11.4.1.3.1. Biosimulation Market: By Application, 2020-2030, USD (Million)

12. Company Profile

  • 12.1. Medtronic
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Initiatives
  • 12.2. Certara USA, Inc.
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Initiatives
  • 12.3. Simulation Plus, Inc.
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategic Initiatives
  • 12.4. Dassault Systems SA
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Initiatives
  • 12.5. Schrodinger, Inc.
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Initiatives
  • 12.6. Advanced Chemistry Development, Inc.
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategic Initiatives
  • 12.7. Chemical Computing Group, Inc.
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Portfolio
    • 12.7.4. Strategic Initiatives
  • 12.8. Physiomics PLC
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Portfolio
    • 12.8.4. Strategic Initiatives
  • 12.9. Entelos, Inc.
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Portfolio
    • 12.9.4. Strategic Initiatives
  • 12.10. Rhenovia Pharma Ltd.
    • 12.10.1. Company Overview
    • 12.10.2. Financial Performance
    • 12.10.3. Product Portfolio
    • 12.10.4. Strategic Initiatives
  • 12.11. Genedata AG
    • 12.11.1. Company Overview
    • 12.11.2. Financial Performance
    • 12.11.3. Product Portfolio
    • 12.11.4. Strategic Initiatives
  • 12.12. Evidera, Inc.
    • 12.12.1. Company Overview
    • 12.12.2. Financial Performance
    • 12.12.3. Product Portfolio
    • 12.12.4. Strategic Initiatives
  • 12.13. In Silico Biosciences Inc.
    • 12.13.1. Company Overview
    • 12.13.2. Financial Performance
    • 12.13.3. Product Portfolio
    • 12.13.4. Strategic Initiatives
  • 12.14. Oxford Drug Design
    • 12.14.1. Company Overview
    • 12.14.2. Financial Performance
    • 12.14.3. Product Portfolio
    • 12.14.4. Strategic Initiatives
  • 12.15. Insilico Biotechnology AG
    • 12.15.1. Company Overview
    • 12.15.2. Financial Performance
    • 12.15.3. Product Portfolio
    • 12.15.4. Strategic Initiatives
  • 12.16. Leadinvent technologies Pvt Ltd.
    • 12.16.1. Company Overview
    • 12.16.2. Financial Performance
    • 12.16.3. Product Portfolio
    • 12.16.4. Strategic Initiatives
  • 12.17. Leadscope, Inc.
    • 12.17.1. Company Overview
    • 12.17.2. Financial Performance
    • 12.17.3. Product Portfolio
    • 12.17.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 2 Global Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 3 Global Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 4 North America Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 5 North America Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 6 North America Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 7 U.S. Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 8 U.S. Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 9 U.S. Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 10 Canada Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 11 Canada Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 12 Canada Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 13 Rest of North America Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 14 Rest of North America Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 15 Rest of North America Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 16 UK and European Union Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 17 UK and European Union Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 18 UK and European Union Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 19 UK Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 20 UK Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 21 UK Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 22 Germany Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 23 Germany Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 24 Germany Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 25 Spain Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 26 Spain Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 27 Spain Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 28 Italy Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 29 Italy Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 30 Italy Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 31 France Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 32 France Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 33 France Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 34 Rest of Europe Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 35 Rest of Europe Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 36 Rest of Europe Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 37 Asia Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 38 Asia Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 39 Asia Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 40 China Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 41 China Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 42 China Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 43 Japan Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 44 Japan Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 45 Japan Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 46 India Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 47 India Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 48 India Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 49 Australia Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 50 Australia Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 51 Australia Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 52 South Korea Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 53 South Korea Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 54 South Korea Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 55 Latin America Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 56 Latin America Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 57 Latin America Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 58 Brazil Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 59 Brazil Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 60 Brazil Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 61 Mexico Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 62 Mexico Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 63 Mexico Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 64 Rest of Latin America Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 65 Rest of Latin America Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 66 Rest of Latin America Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 67 Middle East and Africa Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 68 Middle East and Africa Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 69 Middle East and Africa Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 70 GCC Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 71 GCC Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 72 GCC Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 73 Africa Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 74 Africa Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 75 Africa Biosimulation Market By Drug Development, 2020-2030, USD (Million)
  • TABLE 76 Rest of Middle East and Africa Biosimulation Market By Type, 2020-2030, USD (Million)
  • TABLE 77 Rest of Middle East and Africa Biosimulation Market By Application, 2020-2030, USD (Million)
  • TABLE 78 Rest of Middle East and Africa Biosimulation Market By Drug Development, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Biosimulation Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Biosimulation Market: Quality Assurance
  • FIG. 5 Global Biosimulation Market, By Type, 2021
  • FIG. 6 Global Biosimulation Market, By Application, 2021
  • FIG. 7 Global Biosimulation Market, By Geography, 2021
  • FIG. 8 Market Geographical Opportunity Matrix - Global Biosimulation Market, 2021
  • FIG. 9 Market Positioning of Key Biosimulation Market Players, 2021
  • FIG. 10 Global Biosimulation Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
  • FIG. 11 Global Biosimulation Market, By Type, 2021 Vs 2030, %
  • FIG. 12 Global Biosimulation Market, By Application, 2021 Vs 2030, %
  • FIG. 13 U.S. Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 14 Canada Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 15 Rest of North America Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 16 UK Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 17 Germany Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 18 Spain Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 19 Italy Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 20 France Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 21 Rest of Europe Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 22 China Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 23 Japan Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 24 India Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 25 Australia Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 26 South Korea Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 27 Rest of Asia Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 28 Brazil Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 29 Mexico Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 30 Rest of Latin America Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 31 GCC Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 32 Africa Biosimulation Market (US$ Million), 2020 - 2030
  • FIG. 33 Rest of Middle East and Africa Biosimulation Market (US$ Million), 2020 - 2030